Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab Maintenance in Limited-Stage Small Cell Lung Cancer
NCT04647357Phase 2
Key facts
- Status
- Unknown
- Start
- Nov 2020
- Primary completion
- May 2023
- Modality
- Immune Checkpoint Inhibitors
- Drugs
- adebrelimab
- Conditions
- small cell lung cancer (SCLC)
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
SHR-1316 Arm
Single arm receiving adebrelimab maintenance therapy.
03
Who it enrols
Patients aged 18-75 with histologically confirmed limited-stage small cell lung cancer who have completed at least 2 cycles of platinum-based concurrent chemoradiotherapy without disease progression.
04
Endpoints
Primary
Progression-Free Survival
Beyond the preview
Go deeper on NCT04647357.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04647357.